In Reply.
作者信息
McNamara Mairéad Geraldine, Valle Juan W
机构信息
Division of Cancer Sciences, University of Manchester and Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
出版信息
Oncologist. 2021 May;26(5):e903-e904. doi: 10.1002/onco.13704. Epub 2021 Feb 15.
Abstract
摘要
相似文献
1
In Reply.作为回复。
Oncologist. 2021 May;26(5):e903-e904. doi: 10.1002/onco.13704. Epub 2021 Feb 15.
2
Reply networks on a bulletin board system.公告板系统上的回复网络。
Phys Rev E Stat Nonlin Soft Matter Phys. 2003 Mar;67(3 Pt 2):036117. doi: 10.1103/PhysRevE.67.036117. Epub 2003 Mar 24.
3
Female reply strategies in a duetting Australian bushcricket, Caedicia sp. (Phaneropterinae: Tettigoniidae: Orthoptera).澳大利亚一种二重唱灌丛蟋蟀Caedicia sp.（扇螽亚科：螽斯科：直翅目）中的雌性回应策略
J Exp Biol. 2004 Feb;207(Pt 5):803-11. doi: 10.1242/jeb.00840.
4
Quality and general practitioner satisfaction with reply letters for dementia patients.痴呆症患者回信的质量与全科医生满意度
Qual Prim Care. 2008;16(3):165-70.
5
Training specialists to write appropriate reply letters to general practitioners about patients with medically unexplained physical symptoms; A cluster-randomized trial.培训专家就患有医学上无法解释的身体症状的患者向全科医生撰写恰当的回信；一项整群随机试验。
Patient Educ Couns. 2015 Oct;98(10):1229-35. doi: 10.1016/j.pec.2015.06.021. Epub 2015 Jul 2.
6
Reply letter utilization by secondary level specialists in a municipality in Brazil: a qualitative study.巴西某城市二级专家回复信的使用情况：一项定性研究
Rev Panam Salud Publica. 2007 Feb-Mar;21(2-3):96-110. doi: 10.1590/s1020-49892007000200005.
7
What is a low dose? Response to "Reply to 'The RBE of low-LET radiations' " Reply to the Response to "Reply to 'The RBE of low-LET radiations' " Comment on 'Updated estimates of the proportion of childhood leukaemia incidence in Great Britain that may be caused by natural background ionising radiation' Reply to "Comment on 'Updated estimates of the proportion of childhood leukaemia incidence in Great Britain that may be caused by natural background ionising radiation' ".什么是低剂量？对《对〈低传能线密度辐射的相对生物效应〉的回复》的回复 对《对〈对〈低传能线密度辐射的相对生物效应〉的回复〉的回复》的回应 对《英国儿童白血病发病率中可能由天然本底电离辐射引起的比例的最新估计》的评论 对《对〈英国儿童白血病发病率中可能由天然本底电离辐射引起的比例的最新估计〉的评论》的回复
J Radiol Prot. 2010 Mar;30(1):93-101; author reply 99-101. doi: 10.1088/0952-4746/30/1/L01. Epub 2010 Mar 10.
8
Emoji can facilitate recognition of conveyed indirect meaning.表情符号可以促进对所传达的间接意义的识别。
PLoS One. 2020 Apr 30;15(4):e0232361. doi: 10.1371/journal.pone.0232361. eCollection 2020.
9
Improving clinical handover: Development of a web-based intensive care unit consultation system with structured reply generation.改善临床交接：开发一个具有结构化回复生成功能的基于网络的重症监护病房会诊系统。
BMJ Qual Improv Rep. 2016 Apr 29;5(1). doi: 10.1136/bmjquality.u210292.w4180. eCollection 2016.
10
Audit of consultant physicians' reply letters for referrals to clinics in a tertiary teaching hospital.对一家三级教学医院中会诊医师给转诊至门诊的回复信的审计。
Intern Med J. 2004 Jan-Feb;34(1-2):31-7. doi: 10.1111/j.1444-0903.2004.00424.x.
本文引用的文献
1
In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)".关于“NUC-1031 联合顺铂一线治疗晚期胆管癌患者的 Ib 期研究（ABC-08）”。
Oncologist. 2021 May;26(5):e902. doi: 10.1002/onco.13703. Epub 2021 Feb 15.
2
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).NUC-1031 联合顺铂一线治疗晚期胆道癌（ABC-08）的 Ib 期研究。
Oncologist. 2021 Apr;26(4):e669-e678. doi: 10.1002/onco.13598. Epub 2020 Dec 3.
3
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌（ClarIDHy）：一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
4
NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).NUC-1031/顺铂对比吉西他滨/顺铂治疗未经治疗的局部晚期/转移性胆道癌（NuTide：121）。
Future Oncol. 2020 Jun;16(16):1069-1081. doi: 10.2217/fon-2020-0247. Epub 2020 May 6.
5
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.培米替尼治疗既往治疗过的局部晚期或转移性胆管癌：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
6
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.在晚期癌症患者中，首创类药物 NUC-1031 的抗肿瘤活性：I 期研究结果。
Br J Cancer. 2018 Oct;119(7):815-822. doi: 10.1038/s41416-018-0244-1. Epub 2018 Sep 12.
7
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.二线铂类治疗在卵巢癌患者中的反应率对铂耐药的临床定义提出了挑战。
Gynecol Oncol. 2018 Aug;150(2):239-246. doi: 10.1016/j.ygyno.2018.05.020. Epub 2018 May 26.
8
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.美国临床肿瘤学会临床实践指南更新：白细胞生长因子的应用建议。
J Clin Oncol. 2015 Oct 1;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488. Epub 2015 Jul 13.
9
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.吉西他滨单药或联合顺铂治疗胆道癌患者：日本多中心比较研究。
Br J Cancer. 2010 Aug 10;103(4):469-74. doi: 10.1038/sj.bjc.6605779. Epub 2010 Jul 13.
10
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.顺铂联合吉西他滨与吉西他滨治疗胆管癌。
N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.
Zotero 插件